Article
AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Nature communications - 19 Apr 2022
Shrestha Bhattarai Tripti, Shamu Tambudzai, Gorelick Alexander N, Chang Matthew T, Chakravarty Debyani, Gavrila Elena I, Donoghue Mark T A, Gao JianJong, Patel Swati, Gao Sizhi Paul, Reynolds Margaret H, Phillips Sarah M, Soumerai Tara, Abida Wassim, Hyman David M, Schram Alison M, Solit David B, Smyth Lillian M, Taylor Barry S
Abstract excerpt
AKT- a key molecular regulator of PI-3K signaling pathway, is somatically mutated in diverse solid cancer types, and aberrant AKT activation promotes altered cancer cell growth, survival, and metabolism1-8. The most common of AKT mutations (AKT1 E17K) sensitizes affected solid tumors to AKT inhibitor therapy7,8. However, the pathway dependence and inhibitor sensitivity of the long tail of potentially activating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.